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Is Low CACs Really Different
From Zero.
A Report From the CACTI Study
The use of small Agatston scores to indicate the presence of
coronary artery calcium (CAC) as a marker of atherosclerosis is
controversial and may depend on the study population. Two
studies found increased associations with all-cause mortality and
incident cardiovascular events with low CAC (>0 to 10 AU)
compared with none; however, the study populations were older
(mean ages of 58 and 54 years, respectively) (1,2). In contrast,
another study found no signiﬁcant association between low
CAC (>0 to 10 AU) and incident cardiovascular events in a
younger population (mean age 43 years) (3). The signiﬁcance of
low CAC scores in younger populations is unclear. Therefore,
we examined whether progression of CAC over 6 years was
increased in participants with low CAC compared with in-
dividuals with zero CAC in the CACTI (Coronary Artery
Calciﬁcation in Type 1 Diabetes) study. The CACTI study is a
prospective cohort study of the prevalence and progression of
CAC in a young population of adults with and without type 1
diabetes mellitus (T1DM).Figure 1. Progression of CAC According to Baseline CAC Categories
Percent of participants with progression of coronary artery calcium (CAC) at y
According to the data, more than twice as many study participants with a low
zero CAC score (test for trend p < 0.001). T1D ¼ type 1 diabetes mellitus.(n ¼ 442) or without diabetes (n ¼ 506) who enrolled in the
CACTI study in 2000 to 2002 and completed follow-up after
6 years. All participants reported no diagnosis of cardiovascular
disease and were asymptomatic at enrollment. The protocol was
reviewed and approved by the Colorado Multiple Institutional
Review Board, and informed consent was obtained. The study
has been described in detail elsewhere (4).
CAC was obtained using an ultrafast Imatron C-150XLP
electron beam computed tomography scanner (Imatron, San
Francisco, California). Progression was deﬁned as an increase in
volume of CAC between baseline and follow-up of $2.5 square
root–transformed units (5).
Baseline CAC was categorized as 0, >0 to 10, >10 to 100,
and >100 AU. Multivariate logistic regression was used to
determine the association of baseline CAC on progression of
CAC. All analyses were performed using SAS/STAT software
version 9.3 (SAS Institute, Inc., Cary, North Carolina).
The study population was relatively young at baseline, with
48.8% of participants <40 years of age. Participants with
T1DM were signiﬁcantly younger than participants without
diabetes (37 vs. 41 years; p < 0.001), had lower total cholesterol
(172 vs. 194 mg/dl; p < 0.001), lower low-density lipoprotein
cholesterol (98 mg/dl vs. 117 mg/dl; p < 0.001), higher systolic
blood pressure (117 mm Hg vs. 115 mm Hg; p < 0.001), and
a higher urine albumin creatinine ratio (71 mg/mg vs. 9 mg/mg;ear 6 according to baseline CAC category and diabetes (DM) status.
CAC score (>0 to 10 AU) had CAC progression than participants with
J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 7 , N O . 6 , 2 0 1 4 Letters to the Editor
J U N E 2 0 1 4 : 6 3 2 – 6
633p < 0.001). At the baseline study visit, 64% of participants with
T1DM and 72% of nondiabetic participants had zero CAC on both
baseline scans. In both groups, 16% had low CAC at baseline (>0 to
10 AU).
From baseline to 6 years, CAC progressed in 42% of participants
with T1DM compared with 30% of the nondiabetic participants
(p < 0.001). Figure 1 displays the percent of participants
with CAC progression according to diabetes status and baseline
CAC category, with a signiﬁcant trend across all CAC categories
(p < 0.001).
In logistic regression analysis adjusted for age, sex, diabetes status,
body mass index, glycosylated hemoglobin, and albumin creatinine
ratio, a CAC score >0 to 10 AU was associated with a 2.5-fold
increase in odds for progression (odds ratio: 2.5 [95% conﬁdence
interval: 1.6 to 3.9]). A mild CAC score (>10 to 100 AU) was
associated with a 12-fold increase in odds for progression (odds
ratio: 12.0 [95% conﬁdence interval: 6.2 to 23.1]). The relationship
between baseline CAC and progression did not differ by diabetes
status.
We have shown, in a young population of individuals with
T1DM and a similarly aged group of nondiabetic individuals, that
the presence of CAC at low levels (>0 to 10 AU), is signiﬁcantly
associated with progression over 6 years of follow-up. Although the
risk of the progression of CAC may be modest with low CAC
scores, it is signiﬁcantly higher than for zero CAC. These results are
important for understanding the signiﬁcance of low CAC on
computed tomography scans and for determining clinically impor-
tant values for use in future research.
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Opening: Beyond the
Pressure Gradient
Regurgitation across cardiac valves is driven by the presence
and size of a regurgitant oriﬁce and transvalvular pressure gradient.
Thus, under normal circulatory conditions, aortic regurgitation
is a diastolic phenomenon that occurs in the setting of an incom-
petent aortic valve when pressure in the aorta exceeds that of
the left ventricle. The paradoxical phenomenon of systolic aortic
regurgitation (SAR) has been previously identiﬁed in patients
with arrhythmias, after palliative operations for congenital
heart disease, and in patients with left ventricular assist devices
(LVADs) (1–3).
Herein, we describe a series of 3 cases of SAR in the setting of
continuous ﬂow LVAD (2 patients with the HeartMate II device
[Thoratec Corporation, Pleasanton, California]), and 1 patient with
a HeartWare device (HeartWare International Inc., Framingham,
Massachusetts). Parasternal echocardiographic imaging in the ﬁrst
patient demonstrated trivial systolic aortic valve movement while
purely SAR appears during every heart cycle (Fig. 1A, Online Video 1).
There was no regurgitation during diastole as evidenced by both
parasternal color M-mode (Fig. 1B, arrows) and pulsed-wave
Doppler of the outﬂow tract just below the aortic valve plane
(Fig. 1C, arrows showing SAR but not diastolic aortic regurgita-
tion). In the second patient, aortic regurgitation was trivial but
continuous (Fig. 1D, Online Video 2); color M-mode captured only
SAR (Fig. 1E, arrows). There was continuous regurgitation on
pulsed-wave Doppler, with reduced gradient (lower velocity) but
increased Doppler density in late systole (Fig. 1F, arrows). Finally,
the third patient had continuous aortic regurgitation, with signiﬁ-
cant increase in aortic regurgitation vena contracta during systole
(Figs. 1G and 1H, Online Video 3).
SAR occurred in all 3 patients long after device implantation
(130, 134, and 438 days, respectively). There was no evidence
of device malfunction according to clinical (no change in effort
ability) and echocardiographic (neutral position of the interven-
tricular septum, laminar ﬂow with normal velocities in inﬂow
and outﬂow cannulae) criteria. Cardiac output (estimated from the
right ventricular outﬂow tract diameter and time-velocity integral)
was at the low end of normal (4.8, 4.9, and 5.3 l/min, respectively)
and was unchanged compared with previous echocardiographic
studies.
Presence of SAR in this series of patients with LVADs offers
unique insights into valvular physiology. In all patients, systolic
increase in left ventricular pressure was demonstrated by mitral valve
closure (Online Videos 4, 5 and 6). Conversely, aortic systolic
pressure clearly exceeded ventricular pressure, a fact demonstrated by
the presence of SAR at the time of systolic opening of the aortic
valve. Given that left ventricular pressure cannot induce conven-
tional “valvular opening,” a mechanism other than pressure gradient
must be involved.
